Preserving What Matters: How Institutional Knowledge Protects Value Through M&A

Mergers and acquisitions (M&As) are a defining feature of today’s biopharmaceutical landscape. As companies merge pipelines, teams, and strategies, clinical development programs often undergo significant transitions. Yet during these shifts, one of the most important assets can also be the most fragile: institutional knowledge.

Clinical development is shaped by years of scientific, operational, regulatory, and analytical decisions. Documents record the milestones, but the reasoning behind them lies with the people who have been closest to the program. When ownership changes hands, preserving that accumulated understanding becomes critical to maintaining continuity, ensuring quality, and preventing disruption.

However, during periods of transition, organizations require more than just the retention of knowledge, they need guidance. The right partner not only preserves historical insight but also helps translate it into a clear and efficient path forward. That is where experienced CRO teams provide indispensable value: anchoring programs during uncertainty while helping new ownership accelerate toward future milestones.

This blog examines why institutional knowledge is crucial during M&As, how experienced vendor teams help safeguard it, and what sponsors should consider when preparing for or navigating a transition.

Why Institutional Knowledge Matters During a Transition

Institutional knowledge holds far more than historical facts: it captures judgment. It reflects why protocol changes were made, how certain assumptions shaped analysis strategy, what regulators emphasized in earlier discussions, and which data patterns informed decision-making.

Three principles consistently define why it is so essential:

1. Understanding the journey helps interpret the current state.
   Biopharmaceutical development is nonlinear. Data structures evolve, endpoints shift, and operational strategies adapt to realities observed along the way. A team that has experienced this progression understands not only the final dataset but also the reasoning that led there.

2. Context prevents rework and delays.
   Newly onboarded teams from mergers or otherwise often need time to reconstruct the program’s story — what decisions were made, why they were made, and how earlier phases influence the current requirements. Experienced partners eliminate this relearning cycle by providing continuity and clarity.

3. Stability supports scientific and operational integrity.
   Acquisitions can introduce uncertainty as priorities shift and teams realign. Vendors who have supported the program long-term offer stability, consistency, and a trusted foundation during transition. Continuity isn’t resistance to change… it’s protection of progress.

M&A Transitions Test How Well Knowledge Has Been Preserved

When a clinical program changes ownership, rapid adjustments often follow: new leadership, new processes, new expectations for evidence, and sometimes new development strategies. In these moments, documentation alone rarely conveys the depth of context required for seamless continuation.

Critical information that is difficult to reconstruct includes:

• The rationale behind early protocol modifications

• Historical interpretation of outliers or anomalies

• Previous regulatory feedback and its strategic impact

• Nuances of data transformation and analysis methodology

• lessons learned from operational challenges or site performance

Experienced CRO teams often possess this knowledge more comprehensively than those newly entering the program. Their involvement helps bridge the transition, ensuring the acquiring organization can move forward without losing essential insight — and can make informed, confident decisions about future direction.

Why Maintaining Existing Vendor Partnerships Benefits Acquiring Organizations

For acquiring companies, the challenge is immediate: they inherit responsibility for a program they may not have helped shape. Maintaining continuity with established CRO partners provides several advantages, especially when growth or transformation is the goal.

1. Preservation of the program’s narrative
   Long-term partners understand not only the current evidence but the logic that preceded it. This helps new owners avoid misinterpretations and make more strategic decisions.

2. Faster orientation and reduced onboarding burden
   Experienced teams already possess knowledge of the data, study history, and development trajectory. Their continuity ensures work continues without the delays typically associated with onboarding a new vendor.

3. Continuity across analysis, clinical execution, and regulatory strategy
   Consistency in approach, from data handling to documentation to regulatory expectations, helps prevent gaps or inconsistencies that can emerge during internal restructuring or strategic shifts.

4. Reduced risk during high-stakes moments
   Whether preparing a safety review, responding to agency questions, or integrating multiple study datasets, losing institutional knowledge at the wrong moment can pose a significant risk. Experienced CRO partners safeguard against those vulnerabilities and help ensure critical milestones stay on track.

For acquiring organizations, this continuity can mean the difference between a seamless transition and a prolonged period of reconstruction.

Guiding Growth After the Transition

Preserving institutional knowledge is essential, but successful post-acquisition development also requires transformation. New corporate priorities may emerge: accelerated timelines, expanded indications, new global markets, or revised evidence strategies.

This is where experienced CRO partners provide more than continuity; they offer guidance:

• Translating inherited program history into forward-looking development plans

• Adapting study strategies to align with new organizational goals

• Helping scale clinical or regulatory infrastructure after an acquisition

• Advising on risk areas uncovered during program handover

• Identifying opportunities to streamline or enhance evidence generation

In this phase, institutional knowledge becomes a foundation for growth. and expert guidance becomes the catalyst that helps organizations advance with confidence.

Top 3 Considerations for Sponsors Navigating M&A Transitions

To protect the value of their programs, sponsors should consider the following:

1. Identify where the deepest institutional knowledge lives.
   In many programs, vendor teams have been involved longer than internal staff. Recognizing and retaining those teams strengthens continuity.

   Ask:
   Who understands the program’s evolution most comprehensively?
   
   

2. Preserve continuity where scientific and operational decisions intersect.
   Programs rarely succeed through isolated functions. Experienced partners often connect insights across clinical operations, biometrics, strategy, and regulatory planning.

   Ask:
   Who provides the integrated perspective that supports sound decision-making?
   
   

3. Treat institutional knowledge as an asset worth protecting.
   Acquisitions aim to accelerate progress, not reset it. Preserving the knowledge accumulated across years of development enables new owners to leverage prior investments fully.

   Ask:
   How will continuity strengthen our next phase of development?

Knowledge Fueling Clinical Development

Acquisitions will continue to shape the development of therapies, determine who advances them, and how quickly innovation reaches patients. But while corporate structures may change, the knowledge that fuels meaningful progress must not be lost. Programs thrive when the people and partners who understand their history, data, and decision pathways remain engaged throughout transitions.

With the right continuity, sponsors can navigate M&A events with clarity, preserve the integrity of their scientific and operational narrative, and maintain momentum across even the most complex development pathways. Protecting institutional knowledge is more than a safeguard--  it is a strategic advantage that ensures the next stage of development builds confidently on everything achieved so far.

Veristat: Expert Guidance Through Growth, Transformation, and M&A Transitions

For more than three decades, Veristat has supported development programs through complexity, change, and growth, including transitions driven by mergers and acquisitions. Our teams bring deep scientific, operational, and regulatory expertise across therapeutic areas, and many of our longest-running engagements have continued seamlessly through corporate shifts because we know the data, the story, and the strategy behind each program.

We partner with sponsors to ensure continuity, protect the integrity of their development history, and accelerate the work that matters most. Whether guiding early-phase decisions, managing clinical and data operations, or preparing global submissions, we help teams move forward with confidence, consistency, and context no matter how the corporate landscape evolves.

To discuss how continuity and institutional knowledge can strengthen your development program before, during or after an acquisition or merger, connect with Veristat’s experts by using the link below.

Contact us today to learn more: